EE154 Budget Impact Analysis of Pembrolizumab Plus Enfortumab Vedotin As First-Line Treatment of Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma in USA
Abstract
Authors
Y. Lai H. Guo D. Arku Y. Meng H. Li